CN112203656B - 用于治疗宫颈病症的洛匹那韦和利托那韦 - Google Patents

用于治疗宫颈病症的洛匹那韦和利托那韦 Download PDF

Info

Publication number
CN112203656B
CN112203656B CN201980034993.5A CN201980034993A CN112203656B CN 112203656 B CN112203656 B CN 112203656B CN 201980034993 A CN201980034993 A CN 201980034993A CN 112203656 B CN112203656 B CN 112203656B
Authority
CN
China
Prior art keywords
composition
lopinavir
ritonavir
weeks
cervical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980034993.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN112203656A (zh
Inventor
伊恩·汉普森
琳妮·汉普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Douglas Pharmaceuticals Ltd
Original Assignee
Douglas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Douglas Pharmaceuticals Ltd filed Critical Douglas Pharmaceuticals Ltd
Publication of CN112203656A publication Critical patent/CN112203656A/zh
Application granted granted Critical
Publication of CN112203656B publication Critical patent/CN112203656B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980034993.5A 2018-05-24 2019-05-23 用于治疗宫颈病症的洛匹那韦和利托那韦 Active CN112203656B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1808564.7A GB201808564D0 (en) 2018-05-24 2018-05-24 Treatments
GB1808564.7 2018-05-24
PCT/IB2019/054292 WO2019224779A1 (en) 2018-05-24 2019-05-23 Lopinavir and ritonavir for the treatment of cervix disorders

Publications (2)

Publication Number Publication Date
CN112203656A CN112203656A (zh) 2021-01-08
CN112203656B true CN112203656B (zh) 2024-09-27

Family

ID=62812406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980034993.5A Active CN112203656B (zh) 2018-05-24 2019-05-23 用于治疗宫颈病症的洛匹那韦和利托那韦

Country Status (12)

Country Link
US (2) US11738024B2 (https=)
EP (1) EP3801509A1 (https=)
JP (1) JP7344911B2 (https=)
CN (1) CN112203656B (https=)
AU (1) AU2019274812B2 (https=)
BR (1) BR112020023964A2 (https=)
CA (1) CA3100425A1 (https=)
GB (1) GB201808564D0 (https=)
MX (1) MX2020012656A (https=)
SG (1) SG11202010138WA (https=)
WO (1) WO2019224779A1 (https=)
ZA (1) ZA202006324B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201907305D0 (en) 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
GB201917252D0 (en) * 2019-11-27 2020-01-08 Pharmaceutic compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013034927A1 (en) * 2011-09-09 2013-03-14 The University Of Liverpool Compositions of lopinavir and ritonavir
WO2015059485A1 (en) * 2013-10-23 2015-04-30 The University Of Manchester Treatment of cancer and benign proliferative disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
DK2269591T3 (en) * 2000-01-19 2018-07-16 Abbvie Inc IMPROVED PHARMACEUTICAL FORMULATIONS
CA2445967A1 (en) 2001-05-01 2002-11-07 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
US20030129208A1 (en) 2002-01-07 2003-07-10 Alberts David S. Topical application of alpha-DFMO and anti-inflammatory drug for treatment of actinic keratoses
WO2004010937A2 (en) 2002-07-26 2004-02-05 Advanced Research & Technology Institute At Indiana University Method of treating cancer
BR0302523A (pt) 2003-07-23 2005-04-05 Cristalia Prod Quimicos Farm Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CA2582559A1 (en) 2003-11-28 2005-06-16 The University Of Manchester Treatment of hpv infections and cancer
WO2008088806A1 (en) 2007-01-16 2008-07-24 Johns Hopkins University Combinational paradigm combating hiv, hiv/hsv, or hiv/hpv infections in humans using small molecular weight compounds from plants
EP2280690A2 (en) 2008-04-18 2011-02-09 Nanobio Corporation Methods for treating herpes virus infections
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
KR20130139896A (ko) 2010-09-08 2013-12-23 프로노바 바이오파마 너지 에이에스 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물
WO2016123541A2 (en) 2015-01-30 2016-08-04 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of encephalitis infection
WO2019130341A1 (en) 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201808567D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
GB201808571D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
GB201907305D0 (en) 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
GB201917252D0 (en) 2019-11-27 2020-01-08 Pharmaceutic compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013034927A1 (en) * 2011-09-09 2013-03-14 The University Of Liverpool Compositions of lopinavir and ritonavir
WO2015059485A1 (en) * 2013-10-23 2015-04-30 The University Of Manchester Treatment of cancer and benign proliferative disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir;Hongmei Mo et al.;《Antiviral Research》;第59卷(第3期);摘要，第174页表1 *

Also Published As

Publication number Publication date
AU2019274812A1 (en) 2020-12-10
SG11202010138WA (en) 2020-11-27
ZA202006324B (en) 2022-01-26
US20210213015A1 (en) 2021-07-15
CN112203656A (zh) 2021-01-08
AU2019274812B2 (en) 2024-12-05
US11738024B2 (en) 2023-08-29
JP7344911B2 (ja) 2023-09-14
MX2020012656A (es) 2021-02-02
BR112020023964A2 (pt) 2021-02-23
CA3100425A1 (en) 2019-11-28
GB201808564D0 (en) 2018-07-11
US20240148729A1 (en) 2024-05-09
JP2021525266A (ja) 2021-09-24
WO2019224779A1 (en) 2019-11-28
EP3801509A1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
US20240148729A1 (en) Lopinavir and ritonavir for the treatment of cervix disorders
US10251884B2 (en) Treatment of cancer and benign proliferative disorders
US6197808B1 (en) Methods for treating hyperplasia
TWI574689B (zh) 治療生殖器及肛周疣用之低劑量濃度咪喹莫特調配物及短投藥療法
WO2019224777A1 (en) Pharmaceutical compositions
JP7839091B2 (ja) 医薬組成物
JP2021525263A (ja) 処置
WO2019224776A1 (en) Pharmaceutical compositions
CN113924097A (zh) 包含洛匹那韦的组合物以及对病症的治疗
US20160166682A1 (en) Treatment of Infection
US20250339442A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor
HK1228291B (en) Treatment of cancer and benign proliferative disorders
HK1228291A1 (en) Treatment of cancer and benign proliferative disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant